Donanemab-Azbt Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 350 mg/20 mL
Reference Brands: Kisunla(USA)
Category: Neurology
Donanemab-azbt is a humanized immunoglobulin G1 monoclonal antibody directed against insoluble, N‑truncated pyroglutamate amyloid‑beta found in amyloid plaques in the brains of patients with Alzheimer’s disease. Its mechanism involves binding to these amyloid plaques and facilitating their removal (via microglial-mediated phagocytosis), thereby reducing amyloid burden in the brain. Use of donanemab has been shown to slow cognitive and functional decline in adults with early symptomatic Alzheimer’s disease (mild cognitive impairment or mild dementia) who have confirmed amyloid pathology. Donanemab-azbt is available in Injection and strengths such as 350 mg/20 mL. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Donanemab-azbt is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Donanemab-azbt can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Donanemab-azbt is an experimental drug under investigation for the treatment of Alzheimer’s disease. It is designed to target and remove amyloid-beta plaques in the brain, which are associated with the progression of Alzheimer’s.
It is made from a humanized monoclonal antibody that specifically binds to modified amyloid-beta proteins in the brain.
There is currently no approved trade name, as the drug is still in clinical trials.
Donanemab is developed by Eli Lilly and Company.
The generic name is donanemab-azbt.
No brand name has been assigned yet.
It is manufactured in specialized biopharmaceutical facilities, primarily in the USA, under controlled conditions for clinical development.
Related Products
Donepezil Hydrochloride
Strength:
5 mg, 10 mg, 23 mg
Form: Tablets
Reference Brands: Aricept (USA/EU)
View Details
Acetazolamide Sodium
Strength:
125 mg, 250 mg, 500 mg,
Form: Tablets/ capsules/ Injectable
Reference Brands: Diamox (USA)
View Details
Rimegepant
Strength:
75 mg
Form: Tablets
Reference Brands: Nurtec ODT (USA), Vydura (EU)
View Details
Pimavanserin
Strength:
17 mg, 34 mg, 51 mg
Form: Tablets
Reference Brands: Nuplazid (USA)
View DetailsQuick Response Guaranteed | Verified Suppliers
